Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CANCER THERAPY

A treatment strategy for KRAS-driven tumors

Studies in KRAS-mutant lung and pancreatic adenocarcinoma and in KRAS-amplified gastric carcinoma reveal that SHP2 inhibition augments the antitumor effect of MEK inhibitor treatment.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The effect of SHP2 on the RTK–KRAS–MAPK signaling pathway.

References

  1. Stephen, A. G., Esposito, D., Bagni, R. K. & McCormick, F. Cancer Cell 25, 272–281 (2014).

    Article  PubMed  CAS  Google Scholar 

  2. Mainardi, S. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0023-9 (2018).

  3. Ruess, D. A. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0024-8 (2018).

  4. Wong, G. S. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0022-x (2018).

  5. Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. Nature 503, 548–551 (2013).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Patricelli, M. P. et al. Cancer Discov. 6, 316–329 (2016).

    Article  PubMed  CAS  Google Scholar 

  7. Lito, P. et al. Cancer Cell 25, 697–710 (2014).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Ran, H., Tsutsumi, R., Araki, T. & Neel, B. G. Cancer Cell 30, 194–196 (2016).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Chen, Y. N. et al. Nature 535, 148–152 (2016).

    Article  PubMed  CAS  Google Scholar 

  10. Dardaei, L. et al. Nat. Med. 24, 512–517 (2018).

    Article  PubMed  CAS  Google Scholar 

  11. Drosten, M. et al. EMBO J. 29, 1091–1104 (2010).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Lito, P., Solomon, M., Li, L. S., Hansen, R. & Rosen, N. Science 351, 604–608 (2016).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Acknowledgements

P.L. is supported by the National Institutes of Health (K08 CA191082-01A1), the Damon Runyon Cancer Research Foundation (Clinical Investigator Award), the LUNGevity Foundation (Career Development Award) and the V Foundation (Translational Grant).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Piro Lito.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mai, T.T., Lito, P. A treatment strategy for KRAS-driven tumors. Nat Med 24, 902–904 (2018). https://doi.org/10.1038/s41591-018-0111-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-018-0111-x

This article is cited by

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer